Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.83.
A number of brokerages have recently commented on AQST. Leerink Partnrs raised Aquestive Therapeutics to a “strong-buy” rating in a report on Friday, May 10th. Piper Sandler began coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price for the company. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Friday, July 26th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Finally, SVB Leerink began coverage on Aquestive Therapeutics in a research note on Friday, May 10th. They set an “outperform” rating and a $8.00 target price for the company.
Read Our Latest Stock Analysis on AQST
Institutional Trading of Aquestive Therapeutics
Aquestive Therapeutics Stock Performance
Shares of NASDAQ AQST opened at $3.80 on Wednesday. The firm has a market cap of $345.95 million, a price-to-earnings ratio of -9.05 and a beta of 2.81. The business’s 50-day simple moving average is $2.86 and its 200-day simple moving average is $3.32. Aquestive Therapeutics has a 52 week low of $1.25 and a 52 week high of $6.23.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $12.22 million. During the same quarter last year, the company posted $0.11 earnings per share. As a group, equities research analysts forecast that Aquestive Therapeutics will post -0.49 earnings per share for the current year.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
See Also
- Five stocks we like better than Aquestive Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Where to Find Earnings Call Transcripts
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- How to Calculate Inflation Rate
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.